Theravance Biopharma buy klostergang
Start price
01.12.18
/
50%
€25.26
Target price
04.11.21
€34.28
Performance (%)
-41.40%
End price
17.06.21
€14.80
Summary
This prediction ended on 17.06.21 with a price of €14.80. The BUY prediction by klostergang for Theravance Biopharma performed very badly with a performance of -41.40%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Theravance Biopharma | -1.361% | -1.361% | 51.832% | 65.714% |
| iShares Core DAX® | 2,59 % | 2,69 % | 6,41 % | 53,61 % |
| iShares Nasdaq 100 | -0,91 % | -7,37 % | 20,65 % | 72,78 % |
| iShares Nikkei 225® | 0,15 % | -10,20 % | 46,17 % | 62,43 % |
| iShares S&P 500 | -0,37 % | -0,83 % | 18,02 % | 60,74 % |
Comments by klostergang for this prediction
In the thread Theravance Biopharma diskutieren
klostergang stimmt der Buy-Einschätzung von marge zu
klostergang stimmt am 01.12.2018 der Buy-Einschätzung von marge mit dem Kursziel 55$ zu.
Überschrift: TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]